[HTML][HTML] Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

AA Ferrando, DS Neuberg, J Staunton, ML Loh… - Cancer cell, 2002 - cell.com
AA Ferrando, DS Neuberg, J Staunton, ML Loh, C Huard, SC Raimondi, FG Behm, CH Pui…
Cancer cell, 2002cell.com
Human T cell leukemias can arise from oncogenes activated by specific chromosomal
translocations involving the T cell receptor genes. Here we show that five different T cell
oncogenes (HOX11, TAL1, LYL1, LMO1, and LMO2) are often aberrantly expressed in the
absence of chromosomal abnormalities. Using oligonucleotide microarrays, we identified
several gene expression signatures that were indicative of leukemic arrest at specific stages
of normal thymocyte development: LYL1+ signature (pro-T), HOX11+(early cortical …
Abstract
Human T cell leukemias can arise from oncogenes activated by specific chromosomal translocations involving the T cell receptor genes. Here we show that five different T cell oncogenes (HOX11, TAL1, LYL1, LMO1, and LMO2) are often aberrantly expressed in the absence of chromosomal abnormalities. Using oligonucleotide microarrays, we identified several gene expression signatures that were indicative of leukemic arrest at specific stages of normal thymocyte development: LYL1+ signature (pro-T), HOX11+ (early cortical thymocyte), and TAL1+ (late cortical thymocyte). Hierarchical clustering analysis of gene expression signatures grouped samples according to their shared oncogenic pathways and identified HOX11L2 activation as a novel event in T cell leukemogenesis. These findings have clinical importance, since HOX11 activation is significantly associated with a favorable prognosis, while expression of TAL1, LYL1, or, surprisingly, HOX11L2 confers a much worse response to treatment. Our results illustrate the power of gene expression profiles to elucidate transformation pathways relevant to human leukemia.
cell.com